News for TG Therapeutics, Inc. (0VGI.L)

An analyst from Goldman Sachs, Corinne Johnson, has begun coverage of TG Therapeutics (TGTX) with a Neutral rating and a target price of $37. The firm highlight

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 14 stocks Jim Cramer recently looked at. When a caller inquired about the company during the lightning round, Cramer stated: “I remember when Mike Weiss was an analyst. I always loved the man. I love him now. I think you should buy the stock.” TG Therapeutics, Inc. […]

Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.

TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY. Click to learn about TGTX growth, upcoming trials, and the multiple sclerosis drug market.

US Stock market today saw the Dow jump over 250 points as investors waited for the Federal Reserve interest rate decision, with financial stocks like JPMorgan Chase and Goldman Sachs driving the gains. The S&P 500 and Nasdaq edged slightly higher, while steel stocks rallied on new 50% U.S. tariffs. At the same time, Iran-Israel tensions pushed oil prices close to five-month highs. With no rate hike expected, all eyes are now on the Fed's updated dot plot and Powells press conference. Geopolitical risks and Fed guidance could set the tone for the second half of 2025.

Option market activity for TG Therapeutics (TGTX) shows a notable increase in bullish sentiment, as 7,420 call options were traded, surpassing expectations by 8

Summary TG Therapeutics Inc (TGTX), a biopharmaceutical company specializing in treatments for B-cell diseases, announced that its Chairman and CEO, Michael S.

TG Therapeutics (TGTX) to participate in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Michael S. Weiss to join a fire

**media[647619]**

Summary TG Therapeutics Inc (TGTX), a biopharmaceutical company specializing in treatments for B-cell diseases, announced that its Chairman and CEO, Michael S.

Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX) today announced

Summary TG Therapeutics Inc (TGTX) announced the presentation of data on BRIUMVI® (ublituximab-xiiy) for patients with relapsing forms of multiple sclerosis (R

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy)

Summary TG Therapeutics Inc (TGTX) has announced its presentation schedule for the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, taking p

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublit

TG Therapeutics (TGTX) will present new BRIUMVI® data at the 2025 CMSC Annual Meeting. The key presentations will focus on long-term ublituximab treatm

**media[637912]**

Strengths: FDA approval of BRIUMVI and a robust pipeline of B-cell disease treatments.Weaknesses: Dependence on BRIUMVI sales and the need for additional capit

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]